Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/22/2025

Respiratory Fluoroquinolones for Respiratory Tract Infections

Primary Recommendations by Clinical Setting

  • The American Academy of Pediatrics recommends levofloxacin (500-750 mg once daily) and moxifloxacin (400 mg once daily) for respiratory tract infections, while ciprofloxacin should NOT be used due to inadequate pneumococcal coverage 1, 2, 3
  • For outpatients with comorbidities or recent antibiotic exposure, the Infectious Diseases Society of America recommends levofloxacin 750 mg once daily for 5 days OR 500 mg once daily for 7-14 days 4
  • For hospitalized patients, the Infectious Diseases Society of America recommends levofloxacin 750 mg once daily as monotherapy or moxifloxacin 400 mg once daily as monotherapy 4
  • For ICU patients with severe CAP, the Infectious Diseases Society of America recommends β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either levofloxacin 750 mg daily OR azithromycin 4

Antimicrobial Coverage

  • The American Academy of Pediatrics states that all respiratory fluoroquinolones demonstrate activity against S. pneumoniae, H. influenzae, M. catarrhalis, and atypical pathogens: M. pneumoniae, C. pneumoniae, L. pneumophila 1, 2, 5
  • Resistance surveillance data show virtually no levofloxacin resistance in children younger than 2 years and overall S. pneumoniae resistance to levofloxacin remains <1% in the US 7

Critical Contraindications and Warnings

  • The FDA requires boxed warnings for tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis 7
  • Advanced age increases risk for severe tendon disorders, further increased by concomitant corticosteroid therapy 7

Common Pitfalls to Avoid

  • The American College of Clinical Pharmacy recommends avoiding ciprofloxacin for community-acquired pneumonia due to inadequate pneumococcal coverage and treatment failures 1, 6, 3
  • The Infectious Diseases Society of America recommends using 750 mg daily of levofloxacin for severe pneumococcal infections to overcome resistance mechanisms 2, 6

REFERENCES

2

Respiratory Infection Treatment with Levofloxacin [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Ciprofloxacin Use in Respiratory Infections [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

antimicrobial treatment guidelines for acute bacterial rhinosinusitis. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004

7

Comparison of Levofloxacin and Ciprofloxacin for Various Infections [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025